Recruiting Lymphoma Studies in Atlanta
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability o...
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid ...
DALY II USA/ MB-CART2019.1 for DLBCL
DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractor...
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That h...
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in p...
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refr...
Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma
The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell can...
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
This phase II trial studies the effect of brentuximab vedotin and nivolumab in treating patients with classic Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractor...
About Lymphoma Clinical Trials in Atlanta
Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.
There are currently 8 lymphoma clinical trials recruiting participants in Atlanta, GA. These studies are seeking a combined 1,536 participants. Research is being sponsored by Genmab, Novartis Pharmaceuticals, Miltenyi Biomedicine GmbH and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Lymphoma Clinical Trials in Atlanta — FAQ
Are there lymphoma clinical trials in Atlanta?
Yes, there are 8 lymphoma clinical trials currently recruiting in Atlanta, GA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Atlanta?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Atlanta research site will contact you about next steps.
Are clinical trials in Atlanta free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Atlanta studies also compensate for your time and travel.
What lymphoma treatments are being tested?
The 8 active trials in Atlanta are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.
Data updated March 2, 2026 from ClinicalTrials.gov